Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial

Quality of Life Research

Volumn 8, Issue 5, 1999, Pages 417-426

  Revicki, Dennis A ^a   Genduso, Laura A ^b   Hamilton, Susan H ^b   Ganoczy, Dara ^a   Beasley Jr , Charles M ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 1542641522     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008958925848     Document Type: Article

References (44)

1. 1. Carpenter WT, Buchanan RW. Medical progress: schizophrenia. N Engl J Med 1994; 330: 681-690.
2. 2. Kane JM. Drug therapy: schizophrenia. N Engl J Med 1996; 334: 34-41.
3. 3. Kane JM. Clinical psychopharmacology of schizophrenia. In: Gabbard GO (ed) Treatments for Psychiatric Disorders. Washington, DC: American Psychiatric Press, 1995.
4. 4. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287-302.
5. 5. Dixon LB, Lehman AF, Levine J. Conventional anti-psychotic medications for schizophrenia. Schizophr Bull 1995; 21: 567-578.
6. 6. Awad AG, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997; 11: 32-47.
7. 7. Carpenter WT, Heinrichs DW, Hanlon TE. Methodologic standards for treatment outcomes research in schizophrenia. Am J Psychiatry 1981; 138: 465-471.
8. 8. Collins EJ, Hogan TP, Himansu D. Measurement of therapeutic response in schizophrenia: a critical survey. Schizophr Res 1991; 5: 249-253.
9. 9. Lehman A, Ward N, Linn L. Chronic mental patients: the quality of life issue. Am J Psychiatry 1982; 139: 1271-1276.
10. 10. Lehman A. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40: 369-373.
11. 11. Lehman A, Possidente S, Hawker F. The quality of life of chronic patients in state hospital and in community residences. Hosp Community Psychiatry 1986; 37: 901-907.
12. 12. Sullivan G, Wells K, Leake B. Quality of life of seriously mentally ill persons in Mississippi. Hosp Community Psychiatry 1991; 42: 752-754.
13. 13. Awad AG. Quality of life issues in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H (eds) Contemporary issues in the treatment of schizophrenia. Washington, DC: American Psychiatric Press, 1995: 735-747.
14. 14. Awad AG, Hogan TP, Voruganti LNP et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 (Suppl 3): 123-132.
15. 15. Awad AG, Voruganti LNP, Heslegrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res 1997, in press.
16. 16. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-398.
17. 17. Becker M, Diamond R, Sainfort F. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res 1993, 2: 239-251.
18. 18. Lurie N, Moscovice IS, Finch M, Christianson JB, Popkin MK. Does capitation affect the health of the chronically mentally ill? JAMA 1992; 267: 3300-3304.
19. 19. Awad AG. Subjective response to neuroleptics in schízophrenia. Schizophr Bull 1993; 19: 609-618.
20. 20. Russo J, Trujillo CA, Wingerson D, Decker K, Ries R, Wetzler H, Roy-Byrne P. The MOS 36-item short form health survey: reliability, validity, and preliminary findings in schizophrenic outpatients. Med Care 1998; 36: 752-756.
21. 21. Van Putten T, May PRA, Marder S et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190.
22. 22. Glazer W, Sholomskas D, Williams D et al. Chronic schizophrenics in the community: are they able to report their social adjustment? Am J Orthopsychiatry 1982; 52: 166-171.
23. 23. Voruganti LNP, Heslegrave RJ, Awad AG. Sickness impact profile (SIP) as a measure of patients' quality of life (QOL) in clinical trials involving antipsychotic drugs. 45th Annual Meeting of the American College of Neuropsychopharmacology; 11 15 December 1995; San Juan, Puerto Rico.
24. 24. Dickey B, Wagenaar H, Stewart A. Using health status measures with the seriously mentally ill in health services research. Med Care 1996; 34: 112-116.
25. 25. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996; 11: 101-108.
26. 26. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997; 22: 256-266.
27. 27. Naber D, Walther A, Kirshere T et al. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad AG (eds) Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods. Vienna: Springer Verlag, 1995; 111-122.
28. 28. Meltzer HY, Burnett S, Bastani B, Ramirez I.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Commun Psychiatry 1990; 41: 892-897.
29. 29. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-26.
30. 30. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-815.
31. 31. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharm Bull 1996; 32: 683-697.
32. 32. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998; 18: 41-49.
33. 33. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-465.
34. 34. Woerner MG, Mannuza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112-117.
35. 35. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
36. 36. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Rockville, MD: National Institute of Mental Health, US Department of Health, Education and Welfare, 1976.
37. 37. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
38. 38. Simpson GM, Angus JWS. A rating scale for extrampyramidal side effects. Acta Psychiatr Scand 1970; 212: S11-S19.
39. 39. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
40. 40. Revicki DA. Health care technology assessment and health-related quality of life. In Banta D, Luce BR (eds). Health Care Technology and Its Assessment: An International Perspective. New York: Oxford University Press, 1993.
41. 41. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center 1993.
42. 42. Lehman AF, Postrado LT, Rachuba LT. Convergent validation of quality of life assessments for persons with severe mental illness. Qual Life Res 1993; 2: 327-333.
43. 43. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center 1994.
44. 44. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial of olanzapine. Am J Psychiatry 1997; 154: 466-474.